On Tuesday, the Biden administration announced 10 prescription medications that will be up for price negotiations between federal program Medicare and pharmaceutical manufacturers as part of the Inflation Reduction Act.
The drugs up for negotiation include blood clotting and stroke prevention medications Eliquis and Xarelto, and Type 2 diabetes drugs Jardiance, Januvia and Farxiga.
Heart failure medication Entresto, rheumatoid arthritis drug Enbrel, blood cancer medication Imbruvica, Crohn’s disease treatment Stelara and insulins Fiasp and NovoLog will also be subject to price negotiations.
This will be the first time in Medicare’s 60-year history that it will be able to directly haggle drug pricing with manufacturers.
